izpis_h1_title_alt

Conjugates of monocyclic β-lactams and siderophore mimetics : a patent evaluation (WO2023023393)
ID Krajnc, Alen (Author), ID Gobec, Stanislav (Author)

.pdfPDF - Presentation file, Download (3,28 MB)
MD5: E07AC01825155A294E92CE4A687D2BAF
URLURL - Source URL, Visit https://www.tandfonline.com/doi/full/10.1080/13543776.2023.2262135 This link opens in a new window

Abstract
Introduction: β-Lactams, which include monobactams, remain the most important class of antibiotics worldwide. Aztreonam, the only monobactam in clinical use, has remarkable activity against many Gram-negative bacteria, but limited activity against some of the most problematic multidrug-resistant (MDR) pathogens, such as MDR Pseudomonas aeruginosa and Acinetobacter baumannii co-expressing extended-spectrum- and metallo-β-lactamases, which can inactivate aztreonam by hydrolysis. Areas covered: Structurally novel siderophore-conjugated aztreonam derivatives with improved antibacterial properties against several high-priority pathogens are claimed. This invention reports that sidechain extension of aztreonam is tolerated; the coupling of its aminothiazoloxime carboxylic acid part with a siderophore mimetic significantly improved the antibacterial activity against several problematic strains, including MDR A. baumannii isolates with carbapenemase/cephalosporinase activity. Expert Opinion: Finding new strategies to tackle bacterial resistance to β-lactam antibiotics is critical. Considering that β lactams are validated and safe drugs, this research may stimulate the field to develop new ideas in the arena of antimicrobial drug discovery, particularly with respect to siderophore mimetics.

Language:English
Keywords:antimicrobial resistance, conjugates, aztreonam, anticoagulant, β-lactams, monocyclic β-lactams, siderophores
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:Str. 471-476
Numbering:Vol. 33, no. 7-8
PID:20.500.12556/RUL-152245 This link opens in a new window
UDC:615.015.8
ISSN on article:1354-3776
DOI:10.1080/13543776.2023.2262135 This link opens in a new window
COBISS.SI-ID:171047171 This link opens in a new window
Publication date in RUL:14.11.2023
Views:545
Downloads:48
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Expert opinion on therapeutic patents
Shortened title:Expert opin. ther. pat.
Publisher:Taylor & Francis
ISSN:1354-3776
COBISS.SI-ID:15313959 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:protimikrobna odpornost, aztreonam, konjugati, β-laktami, monociklični β-laktami, siderofori, bakterijska rezistenca, farmacevtska kemija

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:N1-0169
Name:Kovalentni pristop k boju proti bakterijski rezistenci

Funder:ARRS - Slovenian Research Agency
Project number:Z1-4405
Name:Razvoj novih antibiotikov s sočasnim zaviranjem beta-laktamaz in penicilin-vezočih proteinov

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back